"Diakovere Henriettenstift Frauenklinik"
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kentsch, Angela
ADAPTlate, NCT04565054 / 2019-001488-60: Adj. Dyn. Marker-adjusted Personalized Therapy Comparing Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Checkmark [VIRTUAL] ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker—Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (cli.…
Recruiting
3
1250
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
12/27
Keyriched-1, NCT03988036: A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype

Recruiting
2
46
Europe
Pembrolizumab, Keytruda®, Trastuzumab Biosimilar ABP 980, Trazimera®, Pertuzumab, Perjeta®
West German Study Group, Merck Sharp & Dohme Corp., NanoString Technologies, Inc.
Breast Cancer
08/21
12/21
Gillenberg, Anne-Kathrin
Keyriched-1, NCT03988036: A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype

Recruiting
2
46
Europe
Pembrolizumab, Keytruda®, Trastuzumab Biosimilar ABP 980, Trazimera®, Pertuzumab, Perjeta®
West German Study Group, Merck Sharp & Dohme Corp., NanoString Technologies, Inc.
Breast Cancer
08/21
12/21

Download Options